Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · IEX Real-Time Price · USD
507.84
+2.26 (0.45%)
At close: Jun 24, 2022 4:03 PM
507.94
+0.10 (0.02%)
After-hours: Jun 24, 2022 7:40 PM EDT
0.45%
Market Cap 15.06B
Revenue (ttm) 2.90B
Net Income (ttm) -101.13M
Shares Out 29.65M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE 37.88
Dividend n/a
Ex-Dividend Date n/a
Volume 171,276
Open 509.94
Previous Close 505.58
Day's Range 502.71 - 511.89
52-Week Range 462.61 - 832.70
Beta 0.92
Analysts Buy
Price Target 725.90 (+42.9%)
Earnings Date Aug 4, 2022

About BIO

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics,... [Read more...]

Industry Life Sciences Tools & Services
Founded 1952
CEO Norman Schwartz
Employees 7,900
Stock Exchange NYSE
Ticker Symbol BIO
Full Company Profile

Financial Performance

In 2021, BIO's revenue was $2.92 billion, an increase of 14.81% compared to the previous year's $2.55 billion. Earnings were $4.25 billion, an increase of 11.55%.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 725.9, which is an increase of 42.94% from the latest price.

Price Target
$725.9
(42.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid

Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive ...

9 Stocks That Crushed Estimates Are Still Undervalued, Analysts

It's always tough to predict which S&P 500 companies will beat earnings forecasts. But analysts still think you can profit from some that did.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Reports First-Quarter 2022 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the f...

Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More

Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.

Other symbols: LHRMDTMO

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.

Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first...

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.

Bio-Rad (BIO) Loses 15.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Bio-Rad (BIO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwri...

Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginn...

7 Stocks To Buy at the Bottom After the Market Rout

The recent market rout offers an opportune entry point to these seven robust stocks. These are good stocks to buy at their bottom now.

Other symbols: AAPLDEIPAYJPMMRADRYT

All Hail the Balance Sheet Powerhouses

For the past half dozen years, investors couldn't care less about a company's balance sheet.

Other symbols: INCYFSLR

Wall Street Analysts Think Bio-Rad (BIO) Could Surge 42%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive ...

Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Bio-Rad Laboratories (BIO) Q4 Earnings Top Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the f...

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad to Host Investor Day on February 25

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today that it will host an in-per...

Bio-Rad to Report Fourth-Quarter and Full-Year 2021 Financial Results, Thursday, February 10, 2022

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourt...

Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.